Statera Biopharma faces delisting from Nasdaq, allegations of defaulting on loan
FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB) is in danger of being delisted from the Nasdaq exchange after a sustained dip in its stock price and allegations of defaulting on a loan that led to the resignation of two members of its board of directors, according to documents filed with the Securities and Exchange Commission.
Statera is a medical drug company whose leading candidates are designed to treat Crohn’s disease and pancreatic cancer. It first received a delisting notice from Nasdaq on March 23, when it was informed that it was in violation of the bid price rule — the…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
TiFin Group , a Boulder-based financial technology umbrella company, has offloaded its ownership stake in…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
OneOncology, a physician-led national platform for independent oncology practices, has acquired United Urology Group, a…
